It is however quite certain, that the innovation of drugs and devices will continue and the best days for diabetes patients around the world are still ahead.
What are some of the comparisons that a patient should be thinking about, whether or not, when it comes to weight loss, whether to go with, say, one of these GLP-1 medications or maybe something like surgery
Setmelanotide, a selective MC4R agonist, received FDA approval in 2020 specifically for rare genetic obesity syndromes involving POMC or leptin receptor deficiency
doi: 10.1210/jcem.86.4.7402 11 ChengK.W-S ChartW.ButlerB.WeiL.SchoenW
Our GLP-1 Support meals are designed for people using weight loss medications, however people following a Very Low Calorie Diet (VLCD) or post-bariatric surgery often require smaller, protein-rich meals